ADC Therapeutics reported total revenues of $18.839 million for the second quarter ended June 30, 2025, an increase from $17.410 million in Q2 2024. Net product revenues were $18.085 million, up from $17.030 million in the prior year quarter.
The company reported a net loss of $56.646 million for Q2 2025, an increase from $36.544 million in Q2 2024, primarily due to $13.091 million in restructuring, impairment, and other related costs. As of June 30, 2025, cash and cash equivalents stood at $264.560 million, with the recently completed $100 million PIPE financing extending the cash runway into 2028.
Operationally, the company highlighted updated LOTIS-7 data, showing an ORR of 93.3% and a CR of 86.7% across 30 efficacy-evaluable patients, with enrollment expansion underway to 100 patients. The pivotal Phase 3 LOTIS-5 trial is expected to reach its pre-specified progression-free survival events by the end of 2025, with an sBLA filing anticipated in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.